Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

1 results
12:00 AM, Jun 17, 2013  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

2004, Addex and Janssen partnered to discover, develop and commercialize positive allosteric modulators (PAM) of metabotropic glutamate receptor subtype 2
mGluR2) to treat anxiety, schizophrenia and other undisclosed indications. At Dec. 31, 2012, Addex had CHF15.3M …